Human IgG antibody Laboratories manufactures the fence spikes to deter squirrels reagents distributed by Genprice. The Fence Spikes To Deter Squirrels reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike S. Other Fence products are available in stock. Specificity: Fence Category: Spikes Group: To Deter
IgG Antibody to M. Tuberculosis, TB-IgG ELISA Kit |
Creative Diagnostics |
96T |
EUR 676.8 |
Description: This kit is anenzyme-linked immunosorbent assay for qualitative detection of IgG antibodies to Mycobacterium tuberculosis in human serum or plasma. It is intended for diagnosing and monitoring of patients related to infection by M. tuberculosis and other Mycobacteria. |
To Deter information
Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2) |
100992-2 |
BPS Bioscience |
1 mg |
EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. |
Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) |
100731-1 |
BPS Bioscience |
20 µg |
EUR 310 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™. |
Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) |
100731-2 |
BPS Bioscience |
50 µg |
EUR 455 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™. |
Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2) |
100679-1 |
BPS Bioscience |
20 µg |
EUR 305 |
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2) |
100679-2 |
BPS Bioscience |
50 µg |
EUR 450 |
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2) |
100720-1 |
BPS Bioscience |
25 µg |
EUR 295 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation. |
Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2) |
100720-2 |
BPS Bioscience |
50 µg |
EUR 435 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation. |
Spike S1 (B.1.618 Variant), Avi-His-Tag (SARS-CoV-2) |
101126 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.618 originally identified in India, and contains deletions Y145 and H146 as well as mutations E484K and D614G. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. |
Spike S1 (B.1.429 Variant), Avi-His-Tag (SARS-CoV-2) |
101130 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.429, also known as variant Epsilon originally discovered in California (USA), and contains mutations W152C, L452R and D614G. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. |
Spike S1 (B.1.617.2 Variant) Avi-His-Tag (SARS-CoV-2) |
101151-1 |
BPS Bioscience |
100 µg |
EUR 335 |
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.617.2, also known as variant Delta originally discovered in India, and contains mutations T19R, G142D, R158G, L452R, T478K, D614G and P681R as well as deletion E156-F157. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. |
Spike S1 (B.1.617.2 Variant) Avi-His-Tag (SARS-CoV-2) |
101151-2 |
BPS Bioscience |
1 mg |
EUR 2995 |
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.617.2, also known as variant Delta originally discovered in India, and contains mutations T19R, G142D, R158G, L452R, T478K, D614G and P681R as well as deletion E156-F157. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. |
SARS-CoV-2 (COVID-19) Spike 681P Antibody |
9091-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike 681P Antibody |
9091-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Spike S1 (B.1.617 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay Kit |
78288 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The Spike S1 (B.1.617 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.617) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET). |
Spike S1 (B.1.618 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay Kit |
78289 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The Spike S1 (B.1.618 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.618) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET). |